Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Human breast cancer primary tumour tissue RNA-seq

PROVIDER: PRJNA839244 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19262411_1.fastq.gz	Fastqsanger.gz
	SRR19262411_2.fastq.gz	Fastqsanger.gz
	SRR19262412_1.fastq.gz	Fastqsanger.gz
	SRR19262412_2.fastq.gz	Fastqsanger.gz
	SRR19262413_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 46

Similar Datasets

Project description:Microbiome in human breast cancer primary tumour tissue on RNA-seq data

| PRJNA751534 | ENA

RNA Sequencing of two Breast Cancer Cell Lines in Comparison to Healthy Epithelial Breast Cells

Project description:We studied genes, that are differentially expressed between malignant and normal breast tissue, to find weak spots for anti-cancer therapy development. RNA sequencing of three cell lines was performed: MCF-7 (epithelial breast cancer cell line), BCC (primary breast tumour cell line) and MCF-10A (epithelial breast cell line).

2023-01-30 | GSE223718 | GEO

Breast Cancer RNA-seq

Project description:RNA-seq was performed on breast cancer cell lines and primary tumors RNA-seq was performed on 28 breast cancer cell lines, 42 Triple Negative Breast Cancer (TNBC) primary tumors, and 42 Estrogen Receptor Positive (ER+) and HER2 Negative Breast Cancer primary tumors, 30 uninovlved breast tissue samples that were adjacent to ER+ primary tumors, 5 breast tissue samples from reduction mammoplasty procedures performed on patients with no known cancer, and 21 uninvolved breast tissue samples that were adjacent to TNBC primary tumors.

2014-06-11 | E-GEOD-58135 | biostudies-arrayexpress

Integrated single-cell analysis reveals distinct epigenetic-regulated cancer cell states and a heterogeneity-guided core signature in tamoxifen-resistant breast cancer

Project description:Inter- and intra-tumour heterogeneity of breast cancer might be one of the reasons that develops endocrine therapy resistance. Here, we conduct an integrated scRNA-seq and scATAC-seq analysis of ~80K breast tissue cells from two normal (NTs), three primary (PTs) and three tamoxifen-treated recurrent tumour tissues (RTs). We identify distinct cell types among breast tumour tissues and observe a striking level of cell-to-cell heterogeneity among six tumuor tissues and delineates the primary to recurrent tumour progression, underscoring the significance of these single-cell level tumour cell clusters classified from scRNA-seq data. We then define nine cancer cell states (CSs), including five PT-specific, three RT-specific and one PT-RT-shared CSs and identify a heterogeneity-guided core signature. We further identify distinct open chromatin regions and specific transcription factors (TFs) associated with cancer cell states as well as novel biological pathways that mediate their communications with the tumour microenvironment. We finally in silico characterize the core signature and in vitro functionally examine the role of one of core signature, BMP7 suggesting that it plays an oncogenic role in tamoxifen-resistant breast cancer cells, and could be a promising therapeutic target in treating endocrine resistant breast cancer. We envision this integrated single-cell epigenomic and transcriptomic measure will become a powerful approach to unravel how epigenetic factors and tumour microenvironment govern the development of tumour heterogeneity and to uncover potential therapeutic targets that circumvent heterogeneity-related failures.

2024-10-26 | GSE240112 | GEO

RNA-sequencing for dynamic epi-transcriptomic landscape mapping with disease progression in patient primary breast tumours.

Project description:Advanced breast cancer is characterised by enhanced tumour adaptability to therapeutic pressure and the metastatic microenvironment. Transcriptome differences in 14 primary breast tumour samples (n = 14 samples) are uncovered through this comparative RNA-seq analysis of patients that responded well to therapy (n = 7) and patients who had disease recurrence on endocrine treatment (n = 7). RNA sequencing data is deposited as log2 transformed median-of-ratios (DESeq2) normalised counts gene expression values (44934 genes IDs; n = 14 tumour samples).

2023-05-16 | GSE214789 | GEO

Genome-Wide Progesterone Receptor Binding: Cell Type-Specific and Shared Mechanisms in Uterine Fibroids and Breast Cancer (ChIP-Seq)

Project description:Analysis of genes regulated by RU486 (an progesterone antagonist) in human breast cancer T47D cells and human uterine leiomyoma smooth muscle cells. The hypothesis is that RU486 inhibits tumor growth by inactivating the transcription of multiple genes which trigger critical signaling pathways to induce tumorigenesis in both breast caner and uterine leomyoma. Tissue-specific and common patterns of gene regulation may determine the therapeutic effects of antiprogestins in uterine leiomyoma and breast cancer. We applied ChIP-seq to identify PR-interaction sites in T47D breast cancer cells and primary uterine leiomyoma cells treated with RU486.

2012-09-11 | E-GEOD-40724 | biostudies-arrayexpress

Predicting the evolution of metastatic disease in breast cancer: results from 50 years of autopsies

Project description:This is a genomic analysis of breast cancer metastasis using array based CGH and is part of a large study investigating the patterns and evolution of metastases from breast cancer using autopsy material accumulated over the last 50 years from a single institution. The samples used in the genomic profiling comprise the primary breast tumour and multiple matched metastases from each patient. The data demonstrate both the clonal nature of metastatic progression and the role of clonal evolution during progression. This study comprises six patients who died of metastatic breast cancer. For some patients the breast primary tumour and lymph node metastasis was obtained from previous surgical excision, otherwise material was obtained from a resulting autopsy. Each patient set of samples involves the primary breast tumour and multiple metastases, including from lung, liver, lymph node, adrenal gland, brain etc. DNA was extracted from formalin fixed paraffin embedded (FFPE) tissue blocks and analysed for DNA copy number alterations using an Agilent aCGH platform.

2013-11-11 | E-GEOD-46826 | biostudies-arrayexpress

Microarray gene expression profile of primary breast tumour tissue

Project description:Microarray gene expression profile of primary breast tumour tissue

| PRJNA844059 | ENA

Breast cancer proteomics and phosphoproteomics

Project description:Breast cancer tissue pieces from the SCAN-B project were subjected to multiomics analysis. The flow-throughs from RNA seq were here analyzed using protoemics and phosphoproteomics

2026-01-15 | PXD059920 | Pride

MicroRNA expression profiling of human breast cancer identifies new markers of tumour subtype

Project description:MicroRNAs (miRNAs), a class of short non-coding RNAs, often act post-transcriptionally to inhibit gene expression. We used a bead-based flow cytometric profiling method to obtain miRNA expression data for 93 primary human breast tumours, 21 cell lines and five normal breast samples. Of 309 human miRNAs assayed we identify 133 miRNAs expressed in human breast and breast tumours. We used mRNA expression profiling to classify the breast tumours into Luminal A, Luminal B, Basal-like, HER2+/ER- and Normal-like. A number of miRNAs are differentially expressed between these molecular tumour subtypes and individual miRNAs are associated with clinicopathological factors. Furthermore, we find that miRNAs could classify basal versus luminal tumour subtypes in an independent data set. Keywords = miRNA Keywords = microRNA Keywords = normal Keywords = tumour Keywords = cell line Keywords = breast Keywords = cancer Keywords: Bead-based flow cytometric profiling

2007-10-09 | GSE7842 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data